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Abstract
Kdm6a/Utx, a gene on the X chromosome, encodes a histone H3K27me3 demethylase that
has an orthologue on the Y chromosome (Uty) (Zheng et al. 2018). We previously identified
inactivating mutations of Kdm6a in approximately 50% of mouse acute promyelocytic leuke-
mia samples; however, somatic mutations of KDM6A are more rare in human AML samples,
ranging in frequency from 2–15% in different series of patients, where their role in pathogen-
esis is not yet clear. In this study, we show that female Kdm6aflox/flox mice (with allele inacti-
vation initiated by Vav1-Cre in hematopoietic stem and progenitor cells (HSPCs) have a
sex-specific phenotype that emerges with aging, with features resembling a myelodysplastic
syndrome (MDS). Female Kdm6a-knockout (KO) mice have an age-dependent expansion
of their HSPCs with aberrant self-renewal, but they did not differentiate normally into down-
stream progeny. These mice became mildly anemic and thrombocytopenic, but did not
develop overt leukemia, or die from these cytopenias. ChIP-seq and ATAC-seq studies
showed only minor changes in H3K27me3, H3K27ac, H3K4me, H3K4me3 and chromatin
accessibility between Kdm6a-WT and Kdm6a-KO mice. Utilizing scRNA-seq, Kdm6a loss
was linked to the transcriptional repression of genes that mediate hematopoietic cell fate
determination. These data demonstrate that Kdm6a plays an important role in normal hema-
topoiesis, and that its inactivation may contribute to AML pathogenesis.
Introduction
The human KDM6A gene is located on chromosome Xp11.2 and contains a catalytically-active
Jumonji C demethylase domain with activity directed towards the di- and tri-methylated lysine
27 of histone H3 (H3K27) [2]. H3K27 trimethylation is associated with gene silencing, whereas
the trimethylation of H3K4 is associated with gene transcription [3]. KDM6A has established
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roles in development and stem cell differentiation [4–10]. Homozygous constitutive Kdm6a-
null female mice die before embryonic day 13.5. About 25% of Kdm6a-null hemizygous male
mice survive, but are runted and have a reduced lifespan. Kdm6a-null mice apparently die
from cardiac defects, but they also have neural tube defects and anemia/yolk sac abnormalities
[6–8, 11]. KDM6A associates with mixed-lineage leukemia (MLL) 2/3-containing complexes,
which have H3K4 methyltransferase activity [12]; inactivation of KDM6A could therefore lead
to perturbations in H3K4 methylation. Recent work has demonstrated that KDM6A interacts
with KMT2D and p300 (the H3K27 acetyltransferase) in a demethylase-independent manner,
changing the histone marks of enhancers [13]. Therefore, alterations in KDM6A expression
could lead to changes in H3K27 acetylation as well [14].
We previously identified recurrent loss-of-function somatic mutations and deletions of
Kdm6a in a mouse model of acute promyelocytic leukemia [15]. Other groups have identified
inactivating KDM6A mutations in a wide variety of tumor types [16, 17]. In the acute myelo-
cytic leukemia (AML) TCGA dataset, KDM6A somatic mutations were identified in 4 of 200
AML patients [18]. Another large sequencing study reported a lower incidence of KDM6A
driver mutations in AML (10 of 1540 cases), whereas a more recent study used a different gene
panel and reported an incidence of 27% (32 of 119 cases) [19, 20]. KDM6A mutations are
enriched in cases of core-binding factor AML initiated by the RUNX1-RUNX1T1 fusion gene,
where 6–7% of these patients also have mutations in KDM6A [21, 22].
KDM6A mutations also occur in acute lymphoblastic leukemia (ALL), and in chronic mye-
lomonocytic leukemia (CMML) [23–28]. The somatic inactivation of KDM6A has been sug-
gested to cause the dysregulation of HOX, NOTCH, and/or RB signaling pathways, which
could be relevant for leukemogenesis [4, 29–32]. In T-ALL, there is evidence to suggest that
inactivating mutations in KDM6A act via a demethylase-dependent mechanism [28]. How-
ever, it remains unclear how the loss of KDM6A demethylase activity contributes to T-ALL, or
how KDM6A mutations contribute to AML pathogenesis.
In this study, we examined the role of Kdm6a in normal hematopoiesis by inactivating
Kdm6a in the hematopoietic stem and progenitor cells (HSPCs) of adult mice of both sexes,
and defined the epigenetic consequences as a function of age. We also compare the findings in
these mice to that of other previously published mouse models of Kdm6a deficiency [1, 33–
36], to highlight similarities and differences in phenotypes that may be due to how the gene is
inactivated in adult mice (i.e. Cre transgene strategies) or other factors. This study represents
the only described model of inactivation that is hematopoietic-specific, and it has some unique
features that help to define the cell autonomous features of the phenotype.
Methods
Mouse generation
All mice experiments were performed in accordance with institutional guidelines and current
NIH policies and were approved by the Animal Studies Committee at Washington University.
Details for the C57BL/6J mouse strains and husbandry are provided in the supplementary
methods.
Serial replating assay
The serial replating assay was based on previous experiments by Cole et al. [37], and additional
paper-specific details are found in supplementary methods.
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Transplantation assays
BM and spleen cells were harvested and used for transplantation. Additional information
about the transplantation assay can be found in supplementary methods.
Statistics
Unpaired two-tailed Student’s t-test and log-rank test were calculated using Prism 7 software.
P values< 0.05 were considered statistically significant. All data presented the mean ± SD
unless otherwise indicated.
Bioinformatics and associated statistical analysis
The bioinformatics and associated statistical analysis are detailed in the supplementary meth-
ods. For all experiments, additional details can be found in supplementary methods (S1 Meth-
ods). Sequence data is available at NCBI under BioProject PRJNA735514.
Results
Inactivation of Kdm6a causes age- and gender-dependent effects on normal
hematopoiesis
We generated a conditional knockout mouse using ES cells containing a targeted Kdm6aflox
allele obtained from the EUCOMM resource [38]. We crossed Kdm6Aflox/flox mice with
Vav1-Cre transgenic mice to inactivate Kdm6a in HSPCs during mid-gestation (Fig 1A) [39].
All mice were continuously housed in a Specific Pathogen Free (SPF) barrier facility. Our
study included female homozygous (KO-F), female heterozygous (Het-F), male hemizygous
(KO-M), and appropriate age-matched littermate control (WT-F or WT-M) mice. We verified
targeting of the Kdm6a conditional KO allele via whole genome sequencing of DNA isolated
from bulk bone marrow (BM) of a young KO-M mouse. We did not detect Kdm6a protein
expression in BM cells isolated from KO-F or KO-M mice expressing Vav1-Cre (Fig 1B).
We characterized hematopoiesis in young (<12 weeks) and aged (50- to 55-week-old)
Kdm6a conditional KO mice and controls. Complete blood counts (CBCs) revealed mild
thrombocytopenia in young and aged KO-F mice. Aged KO-F mice developed mild macro-
cytic anemia (Fig 1C). There were no significant differences in the blood counts of young or
aged Het-F or KO-M mice (S1A and S1B Fig). Young KO-F mice had mild splenomegaly,
which grew more pronounced with age (Fig 1D). We observed mild splenomegaly in young
KO-M mice, but not in aged KO-M or Het-F mice (S1C Fig). Cytospin preparations of aged
KO-F BM demonstrated increased precursors with binucleated and dysplastic erythroid pre-
cursors, and atypical megakaryocytes, both consistent with myelodysplasia using the Bethesda
Criteria (Fig 1E) [40]. The bone marrow of young and aged KO-F mice showed moderately
increased cellularity with increased numbers of myeloid cells and decreased numbers of ery-
throid cells. The spleens from young KO-F mice had a mild increase in extramedullary eryth-
ropoiesis and granulopoiesis (S1D Fig).
We analyzed frequencies of myeloid, B-, T-, NK, and erythroid precursor cells in BM,
spleen, and peripheral blood (PB). KO-F mice had an increased number of myeloid cells in the
BM and spleen that became more pronounced with age. The frequency of myeloid cells in PB
was increased in aged mice. We found a decreased number of erythroid precursors in BM of
young and aged KO-F mice, which was compensated by an increase of these cells in the spleen
(Fig 1F and 1G). Young and aged Het-F and KO-M mice did not have significant differences
in these populations, with the exception of a mild B-cell reduction in spleens of young KO-M
mice (S2A and S2B Fig).
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Fig 1. The inactivation of Kdm6a in mice had age- and gender-dependent effects on normal hematopoiesis. (A) The targeting strategy of the
Kdm6a conditional knockout allele (Cre-mediated recombination leads to a frameshift mutation that creates a stop codon at exon 6). (B) Western blot
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To determine whether loss of Kdm6a in HSPCs influenced self-renewal, we performed
serial replating assays using whole BM cells isolated from young and aged mice (Fig 2A). BM
cells from young KO-F and KO-M mice displayed a myeloid replating phenotype indicative of
aberrant self-renewal (Fig 2B and 2C). This phenotype was also present in cells derived from
aged mice. Het-F mice acquired an abnormal replating phenotype with age (Fig 2D). Flow
cytometry analysis of BM cells isolated from KO-F mice after two cycles of replating showed a
significant increase in the proportion of mature myeloid cells, compared to control mice in
both young and aged mice (Fig 2E).
To investigate the effects of Kdm6a inactivation on primitive hematopoietic cell populations,
we analyzed progenitor compartments in BM from young or aged Kdm6a conditional KO
mice. We detected an increase in the frequency of HSPCs, as defined by SLAM flow markers in
aged KO-F mice (Fig 3A). There was a significant decrease of the LSK cell population in young
KO-F mice, with a concomitant decrease in multipotent progenitors (MPPs), which remained
significant in aged KO-F mice (Fig 3B). In myeloid progenitors, we observed a decrease in
megakaryocyte-erythrocyte progenitors (MEPs) and an increase in granulocyte-macrophage
progenitors (GMPs). In BM from aged KO-F mice, the MEP compartment remained signifi-
cantly smaller (Fig 3C). The phenotypes described above were specific to KO-F mice and were
not present in KO-M or Het-F mice (S3A–S3D Fig), which indicated that inactivation of
Kdm6a had age- and sex-dependent effects on primitive hematopoietic cell populations.
Because loss of Kdm6a in KO-F mice was associated with a decrease in the LSK compartment,
we characterized cell cycle kinetics and measured apoptosis of that population using flow cytome-
try. The LSK population in young KO-F mice had an increased fraction in the G0/G1 phase of
the cell cycle, and a greater proportion of LSK cells with late apoptotic features (Fig 3D).
Kdm6a conditional KO BM cells have decreased repopulating potential
To evaluate the effects of Kdm6a inactivation on HSPC self-renewal and differentiation in
vivo, we performed competitive transplantation experiments (Fig 4A). We noted a significant
decrease in peripheral blood chimerism in the KO-F donor cell cohort, 4 weeks after trans-
plant. Donor cells from Het-F and KO-M mice had a significant competitive disadvantage
compared to WT competitor donor cells and did not have cell migration or engraftment prob-
lems. However, there may have been cell migration and subtle engraftment problems at an
early timepoint after transplantation that our current assay and measurements did not account
for (Fig 4B). 36 weeks post-transplantation, we assessed donor cell chimerism in BM HSPC
populations and mature cell lineages from all cohorts. There was a selective preservation of
analysis of protein lysate from whole bone marrow (BM) cells showed efficient knockout of Kdm6a in female homozygous (KO-F) and male
hemizygous (KO-M) mice (6–8 weeks old). Data for littermate control mice (WT-F or WT-M) is also presented. (C) Complete blood counts (CBC)
identified mild thrombocytopenia in both young (422.3 K/uL in KO-F mice vs. 793.8 K/uL in WT-F mice, p = 0.0006) and aged (728.9 K/uL in KO-F
mice vs. 1405 K/uL in WT-F mice, p = 0.0028) mice. Aged KO-F mice developed a mild macrocytic anemia, which was characterized by decreased
hemoglobin (Hb: 11.5 g/dL in KO-F mice vs. 14.28 g/dL in WT-F mice, p = 0.0137) with an increased mean corpuscular volume (MCV: 51 fL in KO-F
mice vs. 40.55 fL in WT-F mice, p = 0.0001) and mean corpuscular hemoglobin (MCH: 15.15 pg in KO-F mice vs. 12.85 pg in WT-F mice, p = 0.0004).
(D) Representative images of spleen showed mild splenomegaly in young KO-F mice compared with WT-F mice. These findings were more
pronounced in aged mice. (E) Histopathologic examination of BM with Wright Giemsa staining. Images are representative of 3 independent cytopspin
preparations. Black arrows indicate examples of myelodysplasia. (F) Cell lineage absolute numbers for BM and spleen and frequency for peripheral
blood (PB) from young, KO-F mice and WT-F mice were determined by flow cytometry for myeloid cells, B cells, T cells, NK cells and erythroid
precursors. There was a significant increase in number of Gr1+CD11b+ myeloid cells in BM and spleen in KO-F mice compared to control. In KO-F
mice there was also a significant decrease in Ter119+CD71+ erythroid precursors in BM and significant increase Ter119+CD71+ erythroid precursors in
spleen and PB. (G) Cell lineage absolute numbers for BM and spleen and frequency for PB from aged, KO-F mice and WT-F mice were determined by
flow cytometry for myeloid cells, B cells, T cells, NK cells and erythroid precursors. There was a significant increase in the number of Gr1+CD11b+
myeloid cells in BM, spleen and PB of KO-F mice compared to control. There was a significant decrease in B220+ B cells in the PB of KO-F mice. There
remained a significant decrease in Ter119+CD71+ erythroid precursors in the BM and significant increase in this cell population in spleen and PB in
KO-F mice. Error bars represented mean ± s.d. �p<0.05, ��p<0.01, ���p<0.001 by unpaired two-tailed Student’s t-test.
https://doi.org/10.1371/journal.pone.0255706.g001
PLOS ONE Kdm6a deficiency causes an MDS-like phenotype
PLOS ONE | https://doi.org/10.1371/journal.pone.0255706 November 15, 2021 5 / 25
Fig 2. Kdm6a conditional KO induced aberrant myeloid self-renewal. (A) Experimental schema of the serial
replating assay. Whole BM cells were harvested from young and aged Kdm6a conditional KO mice and appropriate
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CD45.2+ SLAM cells from KO-F donors, compared to a near complete loss of HSPC subpopu-
lations and mature cell lineages. In Het-F and KO-M cohorts, the CD45.2+ SLAM compart-
ment was also preserved (Fig 4C, S4A–S4C Fig).
We tested the repopulating potential of Kdm6a KO donor cells from primary transplants by
performing secondary transplantation using whole BM isolated at the end of the primary
transplants. PB chimerism revealed a more pronounced competitive repopulation disadvan-
tage in donor cells from all cohorts of Kdm6a KO mice (Fig 4D). Preservation of the SLAM
compartment was sustained in secondary transplants using donor cells derived from KO-M
mice at 18 weeks post-transplant (Fig 4E).
The Kdm6a-null stroma promotes the survival of Kdm6a-null
hematopoietic stem and progenitor cells
Since Vav1-Cre inactivates Kdm6aflox/flox alleles in HSPCs (and with the possible exception of
endothelial cells, not other BM stroma cells), and since other models of Kdm6a knockouts
inactivated the gene in both compartments, we wished to define the effect of stromal Kdm6a
inactivation for hematopoietic phenotypes [1, 33, 34, 40, 41]. We therefore performed non-
competitive transplantation experiments using donor cells isolated from the BM of young
Kdm6Aflox/flox x Cre-ERT2+/- mice (with tamoxifen-inducible deletion of Kdm6a), which were
transplanted into young lethally irradiated recipient mice (Fig 5A and 5B). Recipient cohorts
were different from each other based on the presence or absence of Kdm6a conditional KO
and Cre-ERT2+/- alleles. KO-M x Cre-ERT2+/- mice used as recipients would have genetic inac-
tivation of Kdm6a in all tissues (including BM stroma) after tamoxifen administration. We
measured Kdm6a floxing efficiency in BM by performing qPCR, and found that average flox-
ing efficiency was 83.5% 6 weeks after administration of 9 doses of Tamoxifen by gavage (in
cohorts 1 and 2). We detected no Kdm6a floxing in BM isolated from WT-F x Cre-ERT2+/- or
WT-M x Cre-ERT2+/- cohorts not given Tamoxifen, as expected (cohort 4). We detected a flox-
ing efficiency of 11.2% in cohort 3, which was probably due to the presence of Cre-ERT2+/- in
stromal cells of the recipient mice. The KO-F x Cre-ERT2+/- donor and KO-M x Cre-ERT2+/-
recipient cohort (cohort 1) had a significant increase in the LSK and SLAM cell populations,
compared to mice that expressed Kdm6a in the BM alone. A similar trend was seen with an
increase in GMPs, and a decrease in MEPs (Fig 5C and 5D, S5A and S5B Fig). These results
suggest that Kdm6a deficient stroma promotes the expansion of Kdm6a-null HSPCs.
Loss of Kdm6a in hematopoietic cells does not lead to overt leukemia in
Vav1-Cre expressing mice
To determine whether disruption of Kdm6a in HSPCs only (mediated by Vav1-Cre) might
lead to hematopoietic malignancies, we performed an 18-month tumor watch. Kdm6a
littermate controls. 10,000 cells were serially replated in MethoCultTMGF M3534 for 4 weeks. (B-D) Quantification of
colony numbers showed a myeloid replating phenotype in KO-F mice (10.40-fold increase in colonies from KO-F mice
compared to those from WT-F mice after 2 rounds of replating, p = 0.0001) and KO-M mice (4.12-fold increase in
colonies from KO-M mice compared to those from WT-M mice after 2 rounds of replating, p = 0.0001) indicative of
aberrant self-renewal. This was present in both young and aged mice with increased colony numbers at week 2 in
KO-F mice as compared to KO-M mice. Het-F mice only acquired this abnormal replating phenotype with age. (E)
Representative flow cytometry results of BM cells isolated from KO-F mice after two cycles of replating showed a
significant increase in Gr1+CD11b+ myeloid cells as compared to control mice (left panel). Quantification of the
indicated flow cytometry results was significant in cells from both young (12.5-fold increase in KO-F mice compared
to those from WT-F mice, p = 0.0083) and aged mice (2.4-fold increase in KO-F mice compared to those from WT-F
mice, p = 0.0149, right panel). Error bars represented mean ± s.d. �p<0.05, ��p<0.01, ���p<0.001 by unpaired two-
tailed Student’s t-test.
https://doi.org/10.1371/journal.pone.0255706.g002
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Fig 3. Characterization of hematopoietic stem and progenitor cells from BM of young and aged KO-F mice vs. WT-F controls.
(A) Representative flow cytometric plots of BM cells from young and aged KO-F mice and appropriate littermate controls. Profiles
were gated on LSK (Lineage-Sca-1+cKit+) and MP (Lineage-Sca-1-ckit+) populations (black gates) and then the LSK compartment was
PLOS ONE Kdm6a deficiency causes an MDS-like phenotype
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conditional KO mice did not develop spontaneous leukemias, or have an increased incidence
of other cancers compared to control mice (S6A Fig). At the end of the tumor watch, all three
cohorts of Kdm6a KO mice had mild splenomegaly, which was most pronounced in KO-F
mice (S6B Fig). CBCs were essentially unchanged from mice that were 12 months of age (S6C
Fig). Lineage flow cytometry showed infiltration of the spleens with mature myeloid cells and
erythrocyte progenitors, with a concomitant decrease in B and T lymphocytes (S6D Fig).
To test for malignant potential of splenocytes isolated from 18-month-old mice, we did
adoptive transfer experiments using 3 different donors (S6E Fig). Serial analysis of PB and BM
revealed that donor-derived KO-F splenocytes failed to differentiate into mature cell lineages
or give rise to leukemia. However, we detected an increased contribution to primitive hemato-
poietic cell populations from donor-derived cells after long-term observation (S6F Fig).
Epigenetic analyses of Kdm6a-WT and Kdm6a-KO hematopoietic cells
To understand the epigenetic phenotypes of the hematopoietic cells of Kdm6a-null mice, we
used unfractionated BM to perform single-cell RNA-sequencing (scRNA-seq), bulk RNA-
sequencing (RNA-seq), chromatin immunoprecipitation with sequencing (ChIP-seq), and an
assay for transposase-accessible chromatin using sequencing (ATAC-seq). We performed an
ELISA-like profiling assay to assess for differences in total histone H3, and 21 different histone
H3 modifications between young, KO-F mice vs. controls. An analogous assay for total histone
H4 and 10 histone H4 modifications was done using the same samples. We detected no signifi-
cant differences in the modifications tested. We performed immunoblotting using an anti-
H3K27ac Ab, and detected significantly less H3K27ac, using unfractionated BM from young,
KO-F mice vs controls (S7A–S7C Fig). Genome-wide changes in histone modifications were
not apparent between KO-F and WT-F samples at any position of histone marks or ATAC-
seq. We found slightly greater peak occupancy for KO-F samples vs. WT-F samples of
H3K4me peaks using the Kdm6a-null peak calls (S8A–S8E Fig).
Our data included the epigenetic structures of 18,624 transcriptionally-engaged promoters
of annotated genes, defined by significant enrichment of H3K4me3 peaks defined by ChIP-seq
data. When plotted using H3K4me3 peaks from a combination of both genotypes using hierar-
chical clustering or peak density plots, we did not find large scale differences between KO-F
and WT-F samples. DNA accessibility upstream from active promoters was also apparent,
as shown by the distribution of ATAC-seq reads around the transcription start sites (TSS)
(S7D Fig).
We also evaluated histone modifications and DNA accessibility at enhancers. First, we
defined enhancer-like regions and candidate active enhancers using defined epigenetic
sub-gated for SLAM (Lineage-Sca-1+cKit+Cd48-Cd150+, red gates) markers. (B) Quantification of the indicated stem cell and
progenitor compartments showed a significant decrease in absolute number of cells in LSK (1.74-fold decrease in KO-F mice as
compared to WT-F mice, p = 0.0115) and MPP (Lineage-Sca-1+cKit+CD34+Flt3+, 2.71-fold decrease in young KO-F mice as compared
to WT-F mice, p = 0.003) compartments in BM from young KO-F mice. BM from aged KO-F mice had a significant increase in
absolute number of SLAM cells (3.32-fold increase in aged KO-F mice as compared to WT-F mice, p = 0.0150), and a concomitant
decrease in the MPP compartment. (C) Quantification of indicated progenitor compartments showed a significant decrease in absolute
number of cells in the MEP compartment (Lineage-Sca-1-cKit+CD34-FcgRhi, 1.82-fold decrease in KO-F mice as compared to WT-F
mice, p = 0.0087) and increase in GMP compartment (Lineage-Sca-1-cKit+CD34hiFcgRhi, 2.11-fold increase in young KO-F mice as
compared to WT-F mice, p = 0.0082) in BM from young KO-F mice. From aged KO-F mice, the MEP compartment was significantly
decreased. (D) Cell cycle and apoptosis analysis of LSK cell populations from young KO-F mice and appropriate littermate controls by
flow cytometry. Representative flow cytometric plots for apoptosis makers (Annexin V and PI) and cell cycle makers (EdU and
FxCycle). Relative quantification of cell cycle distribution and the proportion of late apoptotic cells in the LSK population showed the
decrease in the LSK compartment in young KO-F mice was associated with a cell cycle shift to the G0/G1 phase (1.26-fold increase in
KO-F mice as compared to WT-F mice, p = 0.0305) and increased apoptosis (4.57-fold increase in KO-F mice as compared to WT-F
mice, p = 0.0040). Error bars represented mean ± s.d. �p<0.05, ��p<0.01, ���p<0.001 by unpaired two-tailed Student’s t-test.
https://doi.org/10.1371/journal.pone.0255706.g003
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Fig 4. Kdm6a conditional KO mice have decreased repopulating potential in serial competitive transplantation assays. (A)
Experimental scheme of a serial competitive repopulation assay. Whole BM cells were harvested from all cohorts of young Kdm6a
PLOS ONE Kdm6a deficiency causes an MDS-like phenotype
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features [42–44]. We identified 14,892 enhancer-like regions with H3K4me peaks, and DNA
accessibility determined by ATAC-seq, excluding promoter-proximal areas near annotated
TSS or with high enrichment of H3K4me3. We categorized enhancer-like regions as “candi-
date-active” enhancer regions (5,559 regions) by including the concomitant presence of
H3K27Ac peaks, or as “candidate-poised” enhancer regions (204 regions) by including the
presence of H3K27me3 peaks. When comparing the candidate active enhancer regions of
WT-F and KO-F mice, the samples were similar in both hierarchical heatmaps and peak den-
sity plots (S7E Fig).
We performed a statistical test on differential histone modifications. Samples did not group
by genotype on a correlation matrix heatmap using the Pearson correlation coefficient. We
found differential changes in H3K27me3, H3K27Ac, H3K4me3, H3K4me, and chromatin
accessibility at 25, 440, 212, 110, and 76 promoters, respectively (FDR < 0.05) (S2 Table). At
enhancers, we found that these chromatin modifications did not cluster by genotype, with the
exception of H3K27Ac, which did group by genotype on a correlation matrix heatmap. We
identified differential changes in H3K27me3, H3K4me, and chromatin accessibility at 19, 2,
and 2 candidate poised enhancers respectively. Additionally, we found differential H3K27Ac
and H3K4me peaks at 188 and 166 candidate active enhancers (S3 Table). Therefore, Kdm6a
loss led to changes in chromatin modifications at a small number of specific loci, but did not
widely disrupt the structure of chromatin throughout the genome.
Kdm6a deficiency alters gene expression in hematopoietic cells
We used scRNA-seq on unfractionated BM cells of 4 young (<12-week-old) female mice (2
WT and 2 littermate matched Kdm6a null mice expressing Vav1-Cre) to infer hematopoietic
cell lineages based on gene expression [45, 46], and to define differentially expressed genes
(DEGs). BM from KO-F mice have an increased fraction of mature myelomonocytic cells,
which include polymorphonuclear neutrophils (PMNs), monocytes, and macrophages. The
largest contribution to the increase in myeloid cells appears to be from monocytes. In contrast,
percentages of B- and T-cells were decreased in KO-F mice (Fig 6A and 6B).
To identify target genes regulated by Kdm6a in young KO-F hematopoietic cells, we first
identified DEGs in pooled cells from all populations, and found 154 DEGs (of which 128 genes
were downregulated) (S4 Table; Fig 6C). We characterized populations with the gene ontol-
ogy (GO) annotation dataset to identify pathways enriched in the DEGs of whole BM. Down-
regulated genes in whole BM showed significant enrichment of immune pathways involved in
antigen processing and T cell differentiation (Fig 6D). To filter for genes involved in myeloid
differentiation, we compared whole BM DEGs with the myeloid cell differentiation GO gene
set, and identified downregulation of Cd74, Ccr7, Itgb3, and upregulation of Fam20c (Fig 6E).
As noted above, we detected very few changes in histone modifications in Kdm6a deficient
conditional KO mice (CD45.2) and mixed with WT competitor marrow (CD45.1 x CD45.2) in a 1:1 ratio, which was then transplanted into
lethally-irradiated primary recipient mice (CD45.1). PB was examined for donor cell chimerism at indicated time points after
transplantation. After 36 weeks of observation, BM cells from primary recipient mice of the same genotype were pooled equally and
transplanted into lethally-irradiated secondary recipient mice. (B) PB donor cell chimerism of primary recipient mice. The respective
curves showed a decreased repopulation potential for all three cohorts of Kdm6a conditional KO mice, which was most pronounced in
KO-F mice. (C) Quantification of donor cell chimerism in hematopoietic stem cells (HSCs) in BM by flow cytometry 36 weeks after
transplantation. A relative preservation of donor-derived cells in the SLAM compartment was found from all cohorts of Kdm6a conditional
KO mice. The most striking difference was found in KO-F mice (35.51-fold increase in SLAM cells as compared to KO-F CD45.2+ donor
cells in whole BM, p = 0.0430). (D) PB donor cell chimerism of secondary recipient mice. (E) Quantification of donor cell chimerism of
HSCs in BM by flow cytometry 18 weeks after secondary transplantation. Significant differences in the chimerism of SLAM cells compared
to whole BM were found in KO-F mice (55.2-fold increase in CD45.2+ KO-F SLAM cells as compared to CD45.2+ cells in the whole BM,
p = 0.0163) and KO-M mice (11.31-fold increase in CD45.2+ KO-M SLAM cells as compared to CD45.2+ cells in the whole BM,
p = 0.0010). Error bars represented mean ± s.d. �p<0.05, ��p<0.01, ���p<0.001 by unpaired two-tailed Student’s t-test.
https://doi.org/10.1371/journal.pone.0255706.g004
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Fig 5. The Kdm6a-null stroma promotes the expression of Kdm6a-null hematopoietic stem and progenitor cells. (A and B)
Experimental scheme of a non-competitive BM repopulation assay. (A) Whole BM cells from indicated donor mice (CD45.2) were
transplanted into lethally-irradiated indicated recipient mice (CD45.2). (B) Recipient mice were given tamoxifen after 4 weeks of
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BM cells. The most significant changes were in H3K27Ac peaks and H3K4me3 peaks near pro-
moters, and H3K4me peaks and H3K27ac peaks near enhancers. When we compared the list
of significantly modified genes from ChIP-seq and scRNA-seq datasets, we found only 9 over-
lapping genes in promoter regions, and 3 overlapping genes (Cd2, Dapk2, and Edaradd) at
enhancer regions (Fig 6F).
Restricting the analysis to PMNs revealed 161 DEGs, of which 125 were downregulated. In
monocytes, we identified 76 DEGs, of which 60 genes were downregulated (S4 Table). We
noted a significant increase in the promyelocyte markers Mpo and Ctsg within the PMN popu-
lation. The most significant DEG in whole BM cells was Vcan, a monocyte marker that was
upregulated in monocyte-specific DEGs (Fig 7A–7C). PMN and monocyte populations were
characterized with the GO annotation dataset. We noted that upregulated PMN genes were
associated with an enrichment in neutrophil migration pathways; downregulated monocyte
genes were associated with antigen processing and presentation pathways (Fig 6D). In PMNs,
we identified downregulation of Cd74, Flvcr1, Itgb3 and upregulation of Ccl3, Fam20c, and
Prtn3 in genes of the myeloid cell differentiation GO gene set. Using the same GO gene set, the
monocyte population displayed reduced expression of Cd74, Irf4, Itgb3, and upregulation of
Hoxa7 (Fig 7A and 7B).
Using scRNA-seq data, we identified a decrease in the fraction of early stem/progenitor
cells and an increase in GMPs of KO-F BM samples (Fig 7D). We identified 211 DEGs in early
stem/progenitor cells, and 82 DEGs in GMPs. When filtering for genes involved in myeloid
differentiation, we identified 5 DEGs in early stem/progenitor cells: 4 genes were downregu-
lated (Gpr171, Lmo2, Meis1, Thra), and 1 was upregulated (Prkdc). In the GMP population,
there were 2 DEGs that overlapped with genes of the myeloid cell differentiation GO gene set:
Ndfip1 was upregulated and Hoxa7 was downregulated (Fig 7F).
Discussion
In this study, we analyzed a Kdm6a conditional knockout mouse model to define the role of
Kdm6a in normal hematopoiesis. Although five previous studies have evaluated Kdm6a defi-
ciency in mouse hematopoietic cells [1, 33–36], this is the first to describe the use of Vav1-Cre
to selectively inactivate Kdm6a in the HSPCs of mid-gestational embryos; surprisingly, the
hematopoietic phenotype in this model is less severe than the others. The Vav1-cre system uti-
lized here has been shown to have little to no off-target recombination, with the possible
exception of endothelial cells. Mice in this study had an MDS-like phenotype that was associ-
ated with increased self-renewal, and was accentuated with aging. Further, Kdm6a inactivation
induced by Vav1-Cre leads to a decreased repopulating potential that is most pronounced in
the BM cells of homozygous female mice. Female Kdm6a KO mice developed an age-depen-
dent expansion of HSPCs, which did not properly differentiate into mature cell types. Finally,
we showed that concurrent Kdm6a inactivation in both BM stromal cells and hematopoietic
cells exaggerated HSPC expansion, suggesting a role for Kdm6a in maintaining the BM micro-
environment. These data may provide a partial explanation for why Kdm6a inactivation in
engraftment to overcome engraftment defect. The Tamoxifen dosing protocol used was 3 mg/day/mouse, MWF x 3 weeks. 6 weeks
after tamoxifen treatment, BM cells were examined by flow cytometry and the percentage of Kdm6a floxed alleles was measured by q-
PCR. Table shows the expected genotype for the BM and stroma cells of the corresponding cohort. (C) Quantification of the indicated
stem cell compartments showed a significant increase in LSK and SLAM cell populations in cohort 1 as compared to all other cohorts.
(D) Quantification of the indicated progenitor compartments showed an increase in GMPs and a decrease in MEPs in cohort 1 as
compared to all other cohorts. Error bars represented mean ± s.d. �p<0.05, ��p<0.01, ���p<0.001, ����p<0.0001 by unpaired two-
tailed Student’s t-test.
https://doi.org/10.1371/journal.pone.0255706.g005
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Fig 6. The loss of Kdm6a alters gene expression in normal hematopoiesis. (A) t-distributed stochastic neighbor embedding (t-SNE) plots of single
cell RNA-seq (scRNA-seq) data from whole BM cells of WT-F mice (n = 2, total cells: 21492) and KO-F mice (n = 2, total cells: 17069). (B)
Population fractions in whole BM cells from KO-F and WT-F mice associated with the scRNA-seq data as defined by Haemopedia gene expression.
Cell populations shown include: PMNs, monocytes, macrophages, Pre-B cells, B cells, T cells and DCs. (C) Volcano plots of expression changes of
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both compartments may have a more severe phenotype in the previously reported models,
with the frequent development of myeloid malignancies.
Five previous studies have reported the consequences of Kdm6a inactivation in hematopoi-
etic cells [1, 33–36]. The strategies used to create these models, and a summary of their pheno-
types, are shown in Table 1. In Thieme et al. [33], the Kdm6a floxed allele was the same as this
study, but floxing was initiated with tamoxifen administration in mice bearing the Rosa-Cre-
ERT2 allele, which is expressed ubiquitously in hematopoietic and stromal cells. Five weeks
after tamoxifen administration, homozygous females exhibited splenomegaly, non-fatal ane-
mia, thrombocytopenia, and leukopenia; hemizygous male mice had no detectable abnormali-
ties. None of these mice were reported to develop leukemias, but they were not followed long-
term. These authors also evaluated the marrow of mice two weeks after tamoxifen administra-
tion: they noted dysplasia of erythroid, megakaryocyte, and granulocyte lineages, and
decreased CFU-GMs, BFU-Es, and CFU-Ms. In contrast, we noted an increase in CFU-GMs,
and no evidence for leukopenia in the Vav1-Cre mouse model.
In the second study, Zheng et al. [1] inactivated Kdm6a by deleting exons 11–14, using
Rosa-Cre-ERT2 mice and tamoxifen to induce somatic floxing; again, floxing occurs ubiqui-
tously in these mice. In this non-transplanted mouse model, approximately 70% of mice (9/12
Kdm6a null female and 7/11 Kdm6a hemizygous males) developed a CMML-like disease with
splenomegaly, monocytosis, and extramedullary hematopoiesis within 12 months after
Tamoxifen administration. Hematopoietic-specific phenotypes were later established with
transplantation, which demonstrated that Kdm6a loss leads to a deficiency in hematopoietic
reconstitution, similar to findings reported here. Because Rosa26 is expressed ubiquitously, the
inactivation of Kdm6a in all tissues (including both hematopoietic and stromal cells) may have
made the myeloid phenotype in these mice more severe, as suggested in our evaluation of
Kdm6a deficiency in out compartment-specific experiments.
Gozdecka et al. [34] demonstrated the novel finding that Kdm6a acts as a tumor suppressor,
but in a noncatalytic fashion. In that study, the same exon 3 Kdm6aflox allele was used, but flox-
ing was initiated by pIpC injection in mice expressing Mx1-Cre. Nearly two thirds of their
non-transplanted, pIpC treated Kdm6a-KO female mice developed a transplantable form of
AML within 22 months. Similar to what is reported here, these authors demonstrated an
increase in lineage negative cells and GMP cells in young female mice, and a decrease in
MEPs. BM cells from both studies showed an expansion of myeloid cells with aberrant self-
renewal.
Sera et al. [35] described a mouse model that conditionally deleted Kdm6a exons 11 and 12,
using tamoxifen inducible ERT2-Cre+ mice. These mice developed an MDS-like phenotype
that was confirmed with morphology and flow cytometry. Although these mice did not
develop spontaneous hematopoietic malignancies, leukemias did arise in mice with additional
mutations created with retrovirus-insertional mutagenesis, using a Moloney murine leukemia
virus fused to a 4070A retrovirus (MOL4070A), that has been shown to promote the develop-
ment of myeloid leukemias [47]. In their experiment, the most common integration sites were
in or near Sox4, Mecom,Osvpl1a, Notch1, Ikaros, and Tax1bp1. Retroviral mutagenesis was ini-
tiated in neonatal female Kdm6a KO mice, hemizygous male Kdm6a KO mice, and female and
male wild type mice. During a 250-day observation period, all male Kdm6a hemizygous
KO-F vs. WT-F from whole BM (FDR< 0.01, FC:> 2 and<-2). Heatmap of z-score values of 154 differentially expressed genes (DEGs) from KO-F
mice compared to WT-F mice by scRNA-seq. (D) Gene ontology (GO) pathway analysis for all DEGs in whole BM, PMNs, and monocytes.(E) Venn
diagram showing the overlap between all DEGs of whole BM and the Myeloid cell differentiation GO gene set (0030099). (F) Venn diagram showing
the overlap between all DEGs of the whole BM scRNA-seq and Chip-seq data for H3K4me3 and H3K27ac promoters (left panel) or H3K4me and
H3K27ac enhancers (right panel). Error bars represented mean ± s.d. ����p<0.0001 by Fisher’s exact test with multiple hypothesis corrections.
https://doi.org/10.1371/journal.pone.0255706.g006
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MOL4070A mice died; all female Kdm6a KO MOL4070A mice died by day 150 (none of the
WT mice died). Most of these mice developed AML (11/13 KO mice and 11/14 hemizygous
mice), but cases of T-ALL (2/13 KO mice and 2/14 hemizygous mice) and B-ALL (1/14 hemi-
zygous mice) were also described. Further, these authors described increased ROS, impaired
DNA damage responses, and upregulation of multiple genes associated with aging in this
model.
Finally, Huppertz et al. [36] recently described a role for Kdm6a in hematopoiesis and B-
cell development under “stressed” conditions. They excised Kdm6a exon 3 utilizing Mx1-cre
transgenic mice and pIpC administration, similar to that of Gozdecka et al. However, this
study followed the mice for only 4–5 months post-pIpC treatment, and did not describe the
development of any malignancies. These authors identified changes in the population sizes of
LSKs, ST-HSCs, MPPs, CMPs, and GMPs that were different than those described in our
model, which could potentially be due to the time at which these assessments were made (16–
20 weeks, vs. <12 or >50 weeks in our study). Similar to our study, no significant changes
were noted in the hematopoietic populations of hemizygous male mice. However, these
authors noted an increase in pro-B cells and decrease of pre-B cells in Kdm6a-KO mice com-
pared to WT. In a competitive transplant environment, the change in B-cell compartments
was only noted after replicative stress was induced by 5-FU.
We have summarized the models and the key findings of these six studies (Table 1) to high-
light how important the experimental design can be for the outcomes of somatic gene inactiva-
tion studies. The results from these six studies have similarities and differences in phenotypes,
with striking differences in the incidence of hematopoietic malignancies in Kdm6a deficient
mice. In our study, none of the mice developed AML, even after long latent periods, while in
other studies, many mice developed AML or a related malignancy. Although it is not clear
what is causing these differences, factors that may contribute include subtle differences in
mouse strains, the hematopoietic and stromal compartments in which floxing occurs, the use
of pIpC to induce floxing in the Mx1-Cre mice, the use of tamoxifen to induce floxing in the
ERT2-Cre mice, and differences in the environments in which mice were housed, among oth-
ers. The importance of these factors is underscored by the fact that four of these studies
(including ours) used ES cells with an identical excision of Kdm6a exon 3. [39] Clearly, one or
more of these factors is highly relevant for the progression to AML (and other phenotypes) in
this model system; additional studies will be required to define the nature and importance of
these factors.
To study the role of the catalytic function of Kdm6a in hematopoietic cells, we used CHIP-
seq to examine global changes in histone methylation and acetylation, using an integrative
approach to define all locations of histone modifications; no large-scale changes in histone
Fig 7. The loss of Kdm6a alters gene expression in early stem/progenitor cells and mature myeloid cells. (A) Volcano plot of
expression changes from KO-F mice vs. WT-F mice in the PMN population at a FDR< 0.01, FC:> 2 and<-2 (left panel). Venn
diagram showing the overlap between all 161 DEGs of the PMN population and the myeloid cell differentiation GO gene set
(0030099) (right panel). (B) Volcano plot of expression changes from KO-F mice vs. WT-F mice in the monocyte population at a
FDR< 0.01, FC:> 2 and<-2 (left panel). Venn diagram showing the overlap between all 76 DEGs of the monocyte population and
the myeloid cell differentiation GO gene set (0030099) (right panel). (C) t-SNE plots showing relative expression of Vcan in whole
BM cells from WT-F and KO-F mice and the relative expression value of Vcan from WT-F vs KO-F mice. (D) t-SNE plots showing
stem and progenitor cells from WT-F mice (total cells:1109) and KO-F mice (total cells: 860). Early stem and progenitor cells in
purple include CFU-E, early B cells, early RBCs, early T-cells, MPP, NP, RBC Prog, ST-HSC. GMP cells are shown in pink.
Population fractions in whole BM cells from KO-F mice and WT-F mice associated with the scRNA-seq data. Data shows early stem
and progenitor cells and GMP cells. (E) Volcano plots of expression changes for KO-F mice vs. WT-F mice from the early stem and
progenitor population or GMP population. For both plots: FDR< 0.01, FC:> 2 and<-2. (F) Venn diagram showing the overlap
between all DEGs of the early stem and progenitor population (211 total DEGs, top diagram) or GMP population (82 total DEGs,
bottom diagram) and the myeloid cell differentiation GO gene set (0030099). Error bars represented mean ± s.d. ����p<0.0001 by
Fisher’s exact test with multiple hypothesis corrections.
https://doi.org/10.1371/journal.pone.0255706.g007
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methylation and/or acetylation were detected. We did identify locus-specific changes, a finding
similar to that of Gozdecka et al, who performed Chip-seq on unfractionated BM samples, and
also on sorted HSPCs. Like Gozdecka et al. and Huppertz et al., we did not find large scale
changes in H3K27me3, supporting a non-catalytic, alternative role for Kdm6a in leukemia
development.
Using scRNA-seq data, we observed that 83% of DEGs in whole BM are downregulated,
supporting a role for Kdm6a as a transcriptional activator. Although previous studies have sug-
gested that Kdm6a can be a transcriptional activator or repressor, these results were based on
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bulk RNA-seq of HSPCs [34]. scRNA-seq allowed us to define population-specific changes,
and we identified many downregulated genes in stem and progenitor cells, PMNs, and mono-
cytes, further suggesting that Kdm6a may normally act as a transcriptional activator in these
compartments. Gozdecka et al. described RNA-seq of sorted HSCs, excluding DEGs found in
male mice at an FDR value of less than 0.05 and a FC: > 0.5 and<-0.5. Using these cutoffs,
they identified 2,886 DEGs, of which approximately half were downregulated (compared to
179 downregulated genes in early stem/progenitor cells in our data); 36 of these downregulated
genes were found in both datasets, and only one common gene was upregulated (Slc41a1).
Additional studies will be required to better understand the roles of DEGs and dysregulated
pathways in Kdm6a deficient HSPCs and myelomonocytic cells.
Our studies have demonstrated that the inactivation of Kdm6a in mice expressing Vav1-
Cre leads to the development of an MDS-like disease that is age and sex dependent. Our data
suggest that Kdm6a may act as a context-dependent tumor suppressor that is important for
maintenance of normal myeloid development, that when disrupted, may contribute to the
pathogenesis of AML.
Supporting information
S1 Fig. Characterization of the Het-F and KO-M mice. (A) CBCs for the young and aged
KO-M mice versus WT-M mice showed no significant differences, except in aged mice which
had an increase in MCV. (B) CBCs for the young and aged Het-F mice versus WT-F mice
showed no significant differences. (C) Splenomegaly was present in young KO-F mice (0.13 g
in KO-F mice versus 0.06 g in WT-F mice, p = 0.0001) and aged KO-F mice (0.212 g in KO-F
mice versus 0.085 g in WT-F mice, p = 0.0062). We also observed mild splenomegaly in young
KO-M mice (0.11 g in KO-M mice versus 0.07 g in WT-M mice, p = 0.0102), but no significant
differences between other matched cohorts. (D) Histopathologic examination of BM and
spleen by H&E staining. BM sections showed moderately to markedly increased numbers of
myeloid cells and decreased numbers of erythroid cells from young to aged KO-F mice. The
myeloid to erythroid ratio was typically elevated, up to 20:1 in some fields. Emperipolesis was
often noted. Megakaryocytes were present in expected to increased numbers. Sections of
spleen from KO-F mice showed extramedullary erythropoiesis and granulopoiesis that
increased with age. Representative images (40x magnification) including small fields (100x
magnification) are shown. Error bars represented mean ± s.d. �p<0.05, ��p<0.01, ���p<0.001
by unpaired two-tailed Student’s t-test.
(PDF)
S2 Fig. Flow cytometry characterization of Het-F and KO-M mice. (A) Cell lineage frequen-
cies for BM, spleen and PB from young and aged, KO-M and WT-M mice were determined by
flow cytometry for myeloid cells, B-cells, T-cells, NK cells and erythroid precursors. There was
a significant decrease in B220+ B cells in the spleen of young KO-M mice as compared to
WT-M mice. (B) Cell lineage frequencies for BM, spleen and PB from young and aged, Het-F
and WT-F mice were determined by flow cytometry for myeloid cells, B cells, T cells, NK cells
and erythroid precursors. There were no significant differences observed in these compart-
ments. Error bars represented mean ± s.d. �p<0.05 by unpaired two-tailed Student’s t-test.
(PDF)
S3 Fig. The inactivation of Kdm6a in mice had age- and gender-dependent effects on prim-
itive hematopoietic cell populations and myeloid progenitors [48]. Flow cytometry analysis
of HSPC populations in young and aged KO-M and Het-F mice (compared with appropriate
littermate controls). Quantification of the indicated stem cell and progenitor compartments
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showed no differences for these genotypes at any time point.
(PDF)
S4 Fig. Kdm6a conditional KO mice had a decreased repopulation potential in serial com-
petitive transplantation. (A) Quantification of donor cell chimerism in mature cell lineage
and myeloid progenitor cell populations each in the PB and BM analyzed by flow cytometry 36
weeks after transplantation showed a nearly complete loss of KO-F donor cells in these cell
populations. (B) Quantification of donor cell chimerism in mature cell lineage and myeloid
progenitor cell populations each in the PB and BM analyzed by flow cytometry 36 weeks after
transplantation showed a significant decrease of KO-M donor cells in these populations. (C)
Quantification of donor cell chimerism in mature cell lineage and myeloid progenitor cell pop-
ulations each in the PB and BM analyzed by flow cytometry 36 weeks after transplantation
showed a significant decrease of Het-F donor cells in these cell populations. Error bars repre-
sented mean ± s.d. �p<0.05, ��p<0.01, ���p<0.001 by unpaired two-tailed Student’s t-test.
(PDF)
S5 Fig. The Kdm6a-null stroma and hematopoietic compartment did not show sex specific
differences. (A) Quantification of the indicated stem cell compartments for cohorts 1–4, sepa-
rated by sex. (B) Quantification of the indicated progenitor compartments for cohorts 1–4,
separated by sex.
(PDF)
S6 Fig. Characterization of 18-month-old Kdm6a conditional KO x Vav1-Cre mice. (A)
The normal survival curve demonstrated that the inactivation of Kdm6a could not induce
mice to develop overt leukemia or die of lethal abnormalities. (B) Spleen weight for all geno-
types of Kdm6a conditional KO mice and appropriate littermate controls. Several KO-F mice
had marked splenomegaly (> 0.5 g). (C) CBCs showed that KO-F mice had anemia and
thrombocytopenia, but no difference was seen in Het-F or KO-M mice. (D) Flow cytometry
analysis of mature cell lineage in the spleen from KO-F and WT-F mice. Representative flow
cytometry plots showed the deletion of Kdm6a caused a striking myeloid skewing with an
increased number of Gr1+CD11b+ myeloid cells and an increase in Ter119+CD71+ erythroid
precursors with age. (E) Experimental scheme of the KO-F spleen cells transplantation. Spleen
cells were harvested from 3 18 months old KO-F donor mice and transplanted into non-irradi-
ated recipient mice. PB was examined for donor cell chimerism on a monthly basis after trans-
plantation. (F) PB donor cell chimerism indicated the donor-derived spleen cells could not
engraft in recipient mice. After long-term observation, mice from each donor cohort were sac-
rificed and BM cells were harvested for flow cytometry analysis. Representative flow cyto-
metric plots and quantification of donor cell chimerism in whole BM and the HSC
compartment (LSK). KO-F donor HSC cells engraft and exhibited a great contribution to the
SLAM compartment (14.6% in LSK cells and 50% in SLAM cells). Error bars represented
mean ± s.d. �p<0.05, ��p<0.01, ���p<0.001 by unpaired two-tailed Student’s t-test.
(PDF)
S7 Fig. Global identification and quantification of H3K4me3, H3K4me, H3K27me3 and
H3K27ac binding profiles at promoter and enhancer-like regions in WT-F and KO-F
mouse models. (A) The detection and quantification of 21 different histone H3 modifications
using total core histone proteins extracted from WT-F and KO-F mice whole BM cells. (B)
The detection and quantification of 10 different histone H4 modifications using total core his-
tone proteins extracted from WT-F and KO-F mice whole BM cells. (C) Western blot analysis
of core histone protein lysates extracted from whole BM cells showed a decrease of H3K27
acetylation in the young KO-F mice compared with WT-F mice. (D) Peak density heat maps
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for each ChIP-seq dataset, ATAC-seq and bulk RNA-seq around the transcription start sites
(TSSs) of the complete set of 18,624 potentially transcriptionally-engaged promoters of anno-
tated genes defined by our own H3K4me3 ChIP-seq dataset. Total peaks detected for H3K27ac
were 33,464 peaks (139,420,356 reads) for WT-F samples and 28,290 peaks (146,408,232 total
reads) for KO-F samples. Tag densities within a window of +/− 10 kb on either side of TSS
coordinates were collected from each dataset. We observed the expected inverse relationship
between H3K4me3 and H3K27me3 peak density that correlates with transcriptional activity of
annotated genes (defined by bulk RNA-seq data) (top panel). Peak density profiles around TSS
(+/− 4kb) for each ChIP-seq dataset with ATAC-seq and bulk RNA-seq (lower panel). (E)
Peak density heat maps for each ChIP-seq dataset and ATAC-seq around enhancer-like
regions of the complete set of 14,892 enhancer-like regions by presence of H3K4me peaks and
ATAC-seq. Tag densities within a window of +/− 10 kb on either side of the enhancer coordi-
nates were collected from each dataset (top panel). The peak density profiles around enhancers
(+/− 4kb) for each ChIP-seq dataset with ATAC-seq (lower panel). Error bars represented
mean ± s.d. �p<0.05 by unpaired two-tailed Student’s t-test.
(PDF)
S8 Fig. Distribution of genome-wide ChIP-seq templates around the annotated TSS. (A)
H3K27me3 ChIP-seq (n = 3 per genotype). (B) H3K27ac ChIP-seq (n = 2 per genotype). (C)
H3K4me ChIP-seq (n = 2 per genotype). (D) H3K4me3 ChIP-seq (n = 3 per genotype). (E)
ATAC-seq (n = 2 per genotype). ChIP-seq and ATAC-seq using bulk BM cells derived from
young, KO-F mice versus young, WT-F mice as controls.
(PDF)
S1 Table. List of antibodies used for flow cytometry with appropriate catalog numbers.
(XLSX)
S2 Table. Promoter list of differential H3K4me3 modification between WT and KO.
(XLSX)
S3 Table. Table of active enhancers of differential modification between Kdm6a-WT and
KO at H3K4 and H3K27.
(XLSX)
S4 Table. Table of differentially expressed genes between WT and KO for bulk bone mar-
row, progenitors, GMPs, PMNs, monocytes, and macrophages.
(XLSX)
S1 Methods. Additional information regarding experimental procedures and material can
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